scholarly journals Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial

Cancer ◽  
2015 ◽  
Vol 121 (20) ◽  
pp. 3717-3726 ◽  
Author(s):  
Anna M. Sawka ◽  
Sharon Straus ◽  
Gary Rodin ◽  
Lineke Heus ◽  
James D. Brierley ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patient ◽  
Randomized Trial ◽  
Decision Aid ◽  
Radioactive Iodine ◽  
Treatment Choice ◽  
Patient Perceptions ◽  
Thyroid Cancer Patient ◽  
Iodine Treatment

scholarly journals Limited adequacy of thyroid cancer patient follow-up at a Canadian tertiary care centre

2013 ◽  
Vol 56 (6) ◽  
pp. 385-392 ◽  
Author(s):  
Elaine Lam ◽  
Scott S. Strugnell ◽  
Chris Bajdik ◽  
Daniel Holmes ◽  
Sam M. Wiseman
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patient ◽  
Tertiary Care ◽  
Care Centre ◽  
Tertiary Care Centre ◽  
Thyroid Cancer Patient

scholarly journals Undetectable Sensitive Serum Thyroglobulin (<0.1 ng/ml) in 163 Patients with Follicular Cell-Derived Thyroid Cancer: Results of rhTSH Stimulation and Neck Ultrasonography and Long-Term Biochemical and Clinical Follow-Up

2012 ◽  
Vol 97 (8) ◽  
pp. 2714-2723 ◽  
Author(s):  
A. M. Chindris ◽  
N. N. Diehl ◽  
J. E. Crook ◽  
V. Fatourechi ◽  
R. C. Smallridge
Keyword(s):  
Thyroid Cancer ◽  
Radioactive Iodine ◽  
Stage Iv ◽  
Needle Aspiration ◽  
Serum Thyroglobulin ◽  
Iodine Treatment ◽  
Long Term Monitoring ◽  
Term Monitoring

Abstract Context: Surveillance of patients with differentiated thyroid cancer (DTC) is achieved using serum thyroglobulin (Tg), neck ultrasonography (US), and recombinant human TSH (rhTSH)-stimulated Tg (Tg-stim). Objective: Our primary aim was to assess the utility of rhTSH Tg-stim in patients with suppressed Tg (Tg-supp) below 0.1 ng/ml using a sensitive assay. Our secondary aims were to assess the utility of US and to summarize the profile of subsequent Tg-supp measures. Design: This is a retrospective study conducted at two sites of an academic institution. Patients: A total of 163 patients status after thyroidectomy and radioactive iodine treatment who had Tg-supp below 0.1 ng/ml and rhTSH Tg-stim within 60 d of each other were included. Results: After rhTSH stimulation, Tg remained below 0.1 ng/ml in 94 (58%) and increased to 0.1–0.5 in 56 (34%), more than 0.5–2.0 in nine (6%), and above 2.0 ng/ml in four (2%) patients. Serial Tg-supp levels were obtained in 138 patients followed over a median of 3.6 yr. Neck US were performed on 153 patients; suspicious exams had fine-needle aspiration (FNA). All positive FNA were identified around the time of the initial rhTSH test. Six of seven recurrences were detected by US (Tg-stim &gt;2.0 ng/ml in one, 0.8 in one and ≤0.5 in four). One stage IV patient had undetectable Tg-stim. Conclusion: In patients with DTC whose T4-suppressed serum Tg is below 0.1 ng/ml, long-term monitoring with annual Tg-supp and periodic neck US are adequate to detect recurrences. In our experience, rhTSH testing does not change management and is not needed in this group of patients.

Metastatic meduller thyroid cancer patient with MEN 2B who developed acute leukemia

2018 ◽  
Author(s):  
Goknur Yorulmaz ◽  
Aysen Akalin ◽  
Toygar Kalkan ◽  
Ilknur Ak Sivrikoz ◽  
Eren Gunduz ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patient ◽  
Acute Leukemia ◽  
Thyroid Cancer Patient ◽  
Men 2B

Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay

2014 ◽  
Vol 406 (11) ◽  
pp. 2733-2738 ◽  
Author(s):  
Silje Bøen Torsetnes ◽  
Marianne Nordlund Broughton ◽  
Elisabeth Paus ◽  
Trine Grønhaug Halvorsen ◽  
Léon Reubsaet
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patient ◽  
Thyroid Cancer Patient
Sign in / Sign up

Export Citation Format

Share Document